Shopping Cart 0
Cart Subtotal
USD 0

Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Mitsubishi Tanabe Pharma Corp (4508)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe's major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp Key Recent Developments

Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science-Toward the Innovative Drug Discovery for refractory Neurological Diseases

Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science

Jul 02,2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds

May 30,2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development

May 30,2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Mitsubishi Tanabe Pharma Corp-Key Facts 6

Mitsubishi Tanabe Pharma Corp-Key Employees 7

Mitsubishi Tanabe Pharma Corp-Key Employee Biographies 8

Mitsubishi Tanabe Pharma Corp-Major Products and Services 9

Mitsubishi Tanabe Pharma Corp-History 11

Mitsubishi Tanabe Pharma Corp-Company Statement 18

Mitsubishi Tanabe Pharma Corp-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Joint Venture 22

Section 2-Company Analysis 23

Company Overview 23

Mitsubishi Tanabe Pharma Corp-Business Description 24

Product Category: Ethical Drugs 24

Performance 24

Product Category: OTC Products 24

Performance 24

Product Category: Others 24

Performance 24

Product Category: Royalty Revenue 25

Performance 25

Geographical Segment: Asia 25

Performance 25

Geographical Segment: Europe 25

Performance 25

Geographical Segment: Japan 25

Performance 25

Geographical Segment: North America 25

Performance 25

Geographical Segment: Others 25

Performance 25

R&D Overview 25

Mitsubishi Tanabe Pharma Corp-Corporate Strategy 26

Mitsubishi Tanabe Pharma Corp-SWOT Analysis 27

SWOT Analysis-Overview 27

Mitsubishi Tanabe Pharma Corp-Strengths 27

Mitsubishi Tanabe Pharma Corp-Weaknesses 28

Mitsubishi Tanabe Pharma Corp-Opportunities 29

Mitsubishi Tanabe Pharma Corp-Threats 30

Mitsubishi Tanabe Pharma Corp-Key Competitors 31

Section 3-Company Financial Ratios 32

Financial Ratios-Capital Market Ratios 32

Financial Ratios-Annual Ratios 33

Performance Chart 36

Financial Performance 36

Financial Ratios-Interim Ratios 37

Financial Ratios-Ratio Charts 38

Section 4-Company's Lifesciences Financial Deals and Alliances 39

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40

Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41

Section 5-Company's Recent Developments 42

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science-Toward the Innovative Drug Discovery for refractory Neurological Diseases 42

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science 43

Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 44

May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development 45

May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 46

Mar 26, 2018: Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development 47

Dec 13, 2017: Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS 48

Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 49

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 51

Sep 29, 2017: MT Pharma: Organizational Change and Personnel Change 52

Section 6-Appendix 53

Methodology 53

Ratio Definitions 53

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Mitsubishi Tanabe Pharma Corp, Performance Chart (2014-2018) 36

Mitsubishi Tanabe Pharma Corp, Ratio Charts 38

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40


List Of Table

List of Tables

Mitsubishi Tanabe Pharma Corp, Key Facts 6

Mitsubishi Tanabe Pharma Corp, Key Employees 7

Mitsubishi Tanabe Pharma Corp, Key Employee Biographies 8

Mitsubishi Tanabe Pharma Corp, Major Products and Services 9

Mitsubishi Tanabe Pharma Corp, History 11

Mitsubishi Tanabe Pharma Corp, Other Locations 19

Mitsubishi Tanabe Pharma Corp, Subsidiaries 20

Mitsubishi Tanabe Pharma Corp, Joint Venture 22

Mitsubishi Tanabe Pharma Corp, Key Competitors 31

Mitsubishi Tanabe Pharma Corp, Ratios based on current share price 32

Mitsubishi Tanabe Pharma Corp, Annual Ratios 33

Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...1) 34

Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...2) 35

Mitsubishi Tanabe Pharma Corp, Interim Ratios 37

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40

Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41

Currency Codes 53

Capital Market Ratios 53

Equity Ratios 54

Profitability Ratios 54

Cost Ratios 55

Liquidity Ratios 55

Leverage Ratios 56

Efficiency Ratios 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mitsubishi Tanabe Pharma Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Tsumura & co

Taisho Pharmaceutical Holdings Co Ltd

Kissei Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Chugai Pharmaceutical Co Ltd

Astellas Pharma Inc